U.S. markets open in 9 hours 30 minutes

CytoDyn Inc. (CYDY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
3.3300-0.1700 (-4.86%)
At close: 3:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.5000
Open3.4600
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range3.2800 - 3.4900
52 Week Range1.6300 - 10.0100
Volume1,500,298
Avg. Volume4,923,306
Market Cap2.041B
Beta (5Y Monthly)-0.64
PE Ratio (TTM)N/A
EPS (TTM)-0.2940
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of CYDY, RIDE, ROOT and VRM
    GlobeNewswire

    FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of CYDY, RIDE, ROOT and VRM

    CEDARHURST, N.Y., April 20, 2021 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Lordstown Motors Corp. (RIDE) Class Period: August 20, 2020 and March 24, 2021Lead Plaintiff Motion Deadline: May 17, 2021SECURITIES FRAUD To learn more, visit https://kclasslaw.com/cases/securities/nasdaqgs-ride/ CytoDyn, Inc. (CYDY) Class Period: March 27, 2020 and March 9, 2021Lead Plaintiff Motion Deadline: May 17, 2021SECURITIES FRAUDTo learn more, visit https://kclasslaw.com/cases/securities/otc-cydy/ Root, Inc. (ROOT)Class Period: October 28, 2020 and March 8, 2021, or shares issued pursuant and/or traceable to the October 2020 Initial Public Offering.Lead Plaintiff Motion Deadline: May 18, 2021SECURITIES FRAUD, MISLEADING PROSPECTUSTo learn more, visit https://kclasslaw.com/cases/securities/nasdaqgs-root/ Vroom, Inc. (VRM)Class Period: November 11, 2020 and March 3, 2021Lead Plaintiff Motion Deadline: May 21, 2021SECURITIES FRAUDTo learn more, visit https://kclasslaw.com/cases/securities/nasdaqgs-vrm/ Shareholders who purchased shares in these companies during the dates listed are encouraged to contact us via the case links above, by calling toll-free at 1-833-835-1495 or by email (dk@kclasslaw.com). If you wish to serve as lead plaintiff with the goal of overseeing the litigation to obtain a fair and just resolution, you must petition the Court on or before the deadlines provided above. Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Kuznicki Law PLLCDaniel Kuznicki, Esq.445 Central Avenue, Suite 344Cedarhurst, NY 11516Email: dk@kclasslaw.comPhone: (347) 696-1134Cell: (347) 690-0692Fax: (347) 348-0967https://kclasslaw.com

  • Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against CytoDyn Inc. (CYDY)
    GlobeNewswire

    Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against CytoDyn Inc. (CYDY)

    RADNOR, Pa., April 20, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Western District of Washington against CytoDyn Inc. (OTCMKTS: CYDY) (“CytoDyn”) on behalf of those who purchased or acquired CytoDyn common stock between March 27, 2020 and March 9, 2021, inclusive (the “Class Period”). Deadline Reminder: Investors who purchased or acquired CytoDyn common stock during the Class Period may, no later than May 17, 2021, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this litigation please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453 or Adrienne Bell, Esq. (484) 270-1435; toll free at (844) 887-9500; via e-mail at info@ktmc.com; or click https://www.ktmc.com/cytodyn-class-action-lawsuit?utm_source=PR&utm_medium=link&utm_campaign=cytodyn. CytoDyn is a biotechnology company that has focused on the development and commercialization of a drug named “Leronlimab” which has long been promoted as a potential therapy for HIV patients. Since the beginning of the global COVID-19 pandemic, CytoDyn began aggressively touting Leronlimab as a treatment for COVID-19. Following CytoDyn’s pivot to hyping Leronlimab as a treatment for COVID-19, CytoDyn’s stock price rose exponentially. Throughout the Class Period, CytoDyn continued to tout Leronlimab as a potential treatment for COVID-19 and to pump up the stock price of CytoDyn while executives aggressively sold shares. Indeed, while CytoDyn’s stock price was sufficiently pumped with the COVID-19 cure hype, long-term shareholders, including defendants Nader Z. Pourhassan, CytoDyn’s Chief Executive Officer, and Michael Mulholland, CytoDyn’s Chief Financial Officer, dumped millions of shares. Following the cash-out by CytoDyn insiders and long-term shareholders, the defendants’ scheme began to unravel. On Friday, March 5, 2021 after the close of trading, and continuing over that weekend, CytoDyn issued press releases describing the results of the Phase IIb/III data on Leronlimab. The press releases had titles such as “CytoDyn to File Accelerated Rolling Review with MHRA and Interim Order (IO) with Health Canada for COVID-19” and “CytoDyn’s Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill COVID-19 Patients Treated with Leronlimab.” However, hidden in the press releases was a disclosure that the primary endpoint of the study—lowering all-cause mortality at Day 28— was not statistically significant. Following the issuance of its press releases, CytoDyn was accused of “massaging the data” and squeezing good news out of a failed study, the results of which CytoDyn reportedly sat on pending regulatory discussions. Following the release of the data, the price of CytoDyn’s common stock fell over 28% to close at $2.91 on March 8, 2021. On March 9, 2021, the price of CytoDyn’s common stock continued to fall, dropping an additional 19% to close at $2.35. The complaint alleges that, throughout the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that CytoDyn’s development and marketing of Leronlimab as a treatment for COVID-19 was not commercially viable. CytoDyn investors may, no later than May 17, 2021, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com. CONTACT: Kessler Topaz Meltzer & Check, LLPJames Maro, Jr., Esq.Adrienne Bell, Esq.280 King of Prussia RoadRadnor, PA 19087(844) 887-9500 (toll free)info@ktmc.com

  • CYTODYN, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York
    PR Newswire

    CYTODYN, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York

    Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against CytoDyn, Inc. ("CytoDyn" or the "Company") (OTCQB: CYDY) in the United States District Court for the Western District of Washington on behalf of those who purchased or acquired the securities of CytoDyn between March 27, 2020 and March 9, 2021,inclusive (the "Class Period").